Komipharm International Co., Ltd. (KOSDAQ:041960)
South Korea
· Delayed Price · Currency is KRW 7,910.00
-440.00 (-5.27%)
At close: Mar 9, 2026
Komipharm International Revenue
Komipharm International had revenue of 12.48B KRW in the quarter ending September 30, 2025, with 13.56% growth. This brings the company's revenue in the last twelve months to 56.30B, up 3.25% year-over-year. In the year 2024, Komipharm International had annual revenue of 58.78B with 37.83% growth.
Revenue (ttm)
56.30B
Revenue Growth
+3.25%
P/S Ratio
10.16
Revenue / Employee
349.70M
Employees
161
Market Cap
572.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 58.78B | 16.13B | 37.83% |
| Dec 31, 2023 | 42.65B | 2.85B | 7.15% |
| Dec 31, 2022 | 39.80B | 3.95B | 11.03% |
| Dec 31, 2021 | 35.85B | -1.31B | -3.53% |
| Dec 31, 2020 | 37.16B | 1.67B | 4.71% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,556.97B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| Sam Chun Dang Pharm. | 220.74B |
| WON TECH | 147.26B |
| Curexo | 27.85B |
| Green Cross Holdings | 2,397.09B |
| i-SENS | 313.10B |